Cows’ Milk Allergy Weaning Guide

Human milk contains bioactive components that confer protection on the newborn. These include complex carbohydrates called Human Milk Oligosaccharides (HMO). Research is revealing the full extent of the beneficial properties of HMOs.

HMOs, the third solid component of human milk, are complex structures with a high potential for specific functions. HMOs and prebiotic oligosaccharides have completely different structures, which impact on their functions. Additionally to prebiotic effects, HMOs reduces adhesion of pathogens and have immune modulator effect.

Cows’ milk allergy (CMA) is one of the major food allergies during infancy and childhood. Hypoallergenic formulas can be necessary for managing infants and children with severe CMA. According to the American Academy of Pediatrics (AAP), a formula is “hypoallergenic” if it does not provoke allergenic activity in 90% of infants or children with confirmed CMA with 95% confid...

There is much confusion between the diagnostic terms ‘lactose intolerance’ and ‘cows’ milk allergy’, which are often used interchangeably, resulting in the potentially incorrect clinical management of these two distinct conditions.

A practical approach to managing a CMA infant with Althera™ Cows’ Milk Allergy (CMA) can occur in 1.8% - 7.5% of infants in the first year of life.1 The allergy is defined as an adverse reaction to the proteins in milk with most children growing out of their allergy by the time they reach one year. The treatment consists of the exclusion of cows’ milk from the infant’s diet. There...

16 weeks old, female twins were identified on EMIS search at a GP practise by an Oviva community dietitian for review. They were not already under the care of a dietitian and had both been started on Neocate LCP® for suspected cows’ milk allergy (CMA) at 6 weeks old by a paediatrician. The dietitian successfully switched both twins to SMA Alfamino and later stepped them down to SMA Althera.

" MANAGING COWS’ MILK PROTEIN ALLERGY WITH ALFAMINO® Overview of cows’ milk protein allergy in infants Cows’ milk protein allergy (CMPA) is one of the most common food allergies in infants.1 Symptoms of CMPA include :  Gastrointestinal (32-60% cases) Skin (5-90%) Anaphylaxis (0.8-9%) Respiratory Many of these symptoms overlap. CMPA can be classified into two groups: IgE mediated or non-IgE mediated (delayed hypersensitiv..."

This symposium took place during the 2018 meeting of the European Academy of Allergy and Clinical Immunology (EAACI). Focussing on the fundamental issues of suboptimal management of patients with cow’s milk protein allergy (CMPA), the speakers discussed key themes for optimising management.

During the last decade, the prevalence of allergic diseases in infants and children has increased significantly either through better awareness of the symptoms or through generally more children being affected.1-3 Therefore, it is no surprise that the numbers of children presenting to clinics in district general hospitals has also increased.4-5 Diagnosis of true milk allergy is key...

Prof O’Mahony began by discussing how the human gut is colonised by a wide diversity of microbes. He went on to review the evidence for how they exhibit highly evolved synergistic relationships to provide essential biological functions to the host and how the gut microbiome is influenced by many factors in early life. Prof Renz proceeded to describe the importance of establishing a s..

Cows’ milk protein allergy (CMPA) is the leading cause of allergy in infants. Previous studies assessing milk formulas with extensively hydrolyzed proteins have reported issues such as reactivity to residual allergens, bitter taste, and the impracticability of adding lactose.

" THE USE OF AMINO ACID FORMULA IN THE DIETARY MANAGEMENT OF SEVERE INFANT COWS’ MILK ALLERGY Approximately 2-7.5% of infants have symptoms of CMA1 whilst symptoms suggestive of Cows’ Milk Allergy (CMA) may be encountered in up to 15% of infants,  emphasising the importance of controlled elimination/milk challenge procedures2. The diagnosis and treatment pathways for cases of CMA are well documented and several guidelines exist to support the healthcare professional in..."